AstraZeneca PLC (AZN.LN) said Thursday that it has received marketing authorization from China’s national medical products administration for Imfinzi for the treatment of patients with stage III nonsmall-cell lung cancer.
The U.K. pharmaceuticals company said approval of Imfinzi is based on results from the primary analysis of progression-free survival and supported by overall survival from the Phase III Pacific trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.